Table 5.

Treatment-emergent adverse events that occurred at least twice in the total safety population of substudy 2

Adverse events (preferred term)	Vehicle (n = 6)	Narsoplimab (n = 6)	All (N = 12)
Fatigue	2 (33.3)	1 (16.7)	3 (25.0)
Upper respiratory tract infection	1 (16.7)	1 (16.7)	2 (16.7)
Metabolic acidosis	2 (33.3)	1 (16.7)	3 (25)
Hyperkalemia	1 (16.7)	1 (16.7)	2 (16.7)
Gout	1 (16.7)	1 (16.7)	2 (16.7)
Diarrhea	1 (16.7)	1 (16.7)	2 (16.7)
Hematochezia	1 (16.7)	1 (16.7)	2 (16.7)
Ligament sprain	1 (16.7)	1 (16.7)	2 (16.7)

Data are n (%).